论文部分内容阅读
目的探讨二甲双胍对糖耐量减低(IGT)患者血脂和血糖的影响作用。方法 134例IGT患者,予二甲双胍治疗,以4周为一疗程,治疗2个疗程。结果治疗一疗程后,空腹血糖无明显变化(P>0.05),餐后2h血糖显著下降(P<0.05),总胆固醇、甘油三脂下降,有统计学意义(P<0.05),低密度脂蛋白、高密度脂蛋白无统计学变化(P>0.05)。BM I无统计学变化(P>0.05)。两疗程后患者的空腹血糖无明显变化(P>0.05),餐后2h血糖均显著下降(P<0.01),总胆固醇、甘油三酯、低密度脂蛋白显著下降(P<0.01),而高密度脂蛋白无明显变化,BM I显著下降。结论二甲双胍可降低IGT患者的血糖、血脂,用药4周后即可发挥作用,用药8周后可达到显效,并可降低体重指数。
Objective To investigate the effect of metformin on blood lipids and blood glucose in patients with impaired glucose tolerance (IGT). Methods A total of 134 patients with IGT were treated with metformin for 4 weeks as a course of treatment for 2 courses of treatment. Results After one course of treatment, there was no significant difference in fasting blood glucose (P> 0.05), blood glucose at 2h after meal decreased significantly (P <0.05), total cholesterol and triglyceride decreased (P <0.05) Protein and HDL had no statistical difference (P> 0.05). BM I did not change statistically (P> 0.05). After two courses of treatment, there was no significant difference in fasting blood glucose between the two groups (P> 0.05), blood glucose at 2h after meal decreased significantly (P <0.01), total cholesterol, triglyceride and low density lipoprotein decreased significantly There was no significant change in density lipoprotein, BM I decreased significantly. Conclusion Metformin can reduce blood glucose and blood lipid in patients with IGT. After 4 weeks of treatment, metformin can exert its effect. After 8 weeks of treatment, metformin can achieve marked effect and reduce body mass index.